Regeneron Pharmaceuticals and Alnylam Pharmaceuticals side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Regeneron Pharmaceuticals | Alnylam Pharmaceuticals |
|---|---|---|
| Phase 1 | Regeneron Pharmaceuticals: 8 of its 43 programs at phase 1 and 3 more — sign in to see them all | Alnylam Pharmaceuticals: 4 of its 11 programs at phase 1 |
| Phase 2 | Regeneron Pharmaceuticals: 16 of its 43 programs at phase 2
and 11 more — sign in to see them all | Alnylam Pharmaceuticals: 5 of its 11 programs at phase 2
|
| Phase 3 | Regeneron Pharmaceuticals: 15 of its 43 programs at phase 3
and 10 more — sign in to see them all | Alnylam Pharmaceuticals: 2 of its 11 programs at phase 3
|
| Approved, new studies | Regeneron Pharmaceuticals: 4 of its 43 programs at approved, new studies
| 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals14 readouts · 4 phase 3 | · | Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion
| Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion
| Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion
| · | · |
| Alnylam Pharmaceuticals6 readouts · 0 phase 3 | · | Alnylam Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion
| · | · | · | Alnylam Pharmaceuticals, Apr ’27: 1 program whose next study reaches primary completion
| Alnylam Pharmaceuticals, May ’27: 1 program whose next study reaches primary completion
| Alnylam Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion
| Alnylam Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion
| Alnylam Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion
| · | · |
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Regeneron Pharmaceuticals
New programs 5
- REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
- REGN13089phase 2 · first study · Oct 2 · Carcinoma, Renal Cell
- REGN24493phase 1 · first study · Sep 30 · Graves Disease
- REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
- ALN-6457phase 2 · first study · Sep 16 · Dementia
Reached a new phase 2
- olatorepatidephase 3 · Oct 19 · Obesity
- ALN-CIDEBphase 3 · Sep 28 · Non-alcoholic Fatty Liver Disease
Study stopped 0
None
Primary completion later 6
- odronextamabphase 3 · Feb 2028 → Feb 2028 (+1 mo) · moved Nov 12 · NCT06091254
- cemiplimabphase 2 · Oct 2029 → Oct 2030 (+12 mo) · moved Nov 10 · NCT06848088
- fianlimabphase 2 · Oct 2029 → Oct 2030 (+12 mo) · moved Nov 10 · NCT06848088
- fianlimabphase 3 · Jul 2026 → Jan 2027 (+6 mo) · moved Nov 10 · NCT05608291
- garetosmabphase 3 · Dec 2028 → Jul 2030 (+19 mo) · moved Oct 8 · NCT07559513
- mibavademabphase 2 · Aug 2027 → Jan 2028 (+5 mo) · moved Oct 1 · NCT07235917
Alnylam Pharmaceuticals
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.
| Condition | Regeneron Pharmaceuticals | Alnylam Pharmaceuticals |
|---|---|---|
| Obesityboth · compare here | Regeneron Pharmaceuticals in Obesity: 5 programs
Their studies: Regeneron Pharmaceuticals’ studies of Obesity in search | Alnylam Pharmaceuticals in Obesity: 3 programs Their studies: Alnylam Pharmaceuticals’ studies of Obesity in search |
| Hypertensionboth · compare here | Regeneron Pharmaceuticals in Hypertension: 1 program
Their studies: Regeneron Pharmaceuticals’ studies of Hypertension in search | Alnylam Pharmaceuticals in Hypertension: 2 programs
Their studies: Alnylam Pharmaceuticals’ studies of Hypertension in search |
| Diabetes Mellitus, Type 2both · compare here | Regeneron Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program
Their studies: Regeneron Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search | Alnylam Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program
Their studies: Alnylam Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.